Registry for patients with advanced metastatic breast cancer in Southeast Netherlands
Southeast Netherlands Advanced Breast Cancer Registry
Academisch Ziekenhuis Maastricht · NCT03577197
This study is gathering information from patients with advanced breast cancer in Southeast Netherlands to see how different treatments are working in real life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 7000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Academisch Ziekenhuis Maastricht (other) |
| Locations | 1 site (Maastricht) |
| Trial ID | NCT03577197 on ClinicalTrials.gov |
What this trial studies
The Southeast Netherlands Advanced Breast Cancer Registry (SONABRE) is an observational cohort study that aims to include all patients diagnosed with advanced breast cancer since 2007 across 11 hospitals in the Southeast Netherlands. Trained clerks collect retrospective data from electronic medical records, focusing on patient demographics, tumor characteristics, treatment modalities, and outcomes. This registry facilitates real-life studies on the safety and effectiveness of various systemic treatments for advanced breast cancer. The data collected will help improve understanding and management of this condition.
Who should consider this trial
Good fit: Ideal candidates for this registry are patients aged 18 and older who have been diagnosed with de novo or recurrent advanced breast cancer since 2007.
Not a fit: Patients who do not have a diagnosis of advanced breast cancer or were treated outside the participating hospitals may not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could enhance treatment strategies and outcomes for patients with advanced metastatic breast cancer.
How similar studies have performed: Other registries focusing on advanced breast cancer have shown success in providing valuable insights into treatment outcomes and patient management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with de novo or recurrent advanced breast cancer since 2007 * Diagnosed with or treated for advanced breast cancer in one of the participating hospitals * Participating hospitals (period of inclusion): Maastricht UMC+ (2007-2025), Zuyderland hospitals Sittard/Heerlen (2007-2025), Amphia Hospital Breda (2013-2025), Catharina Hospital Eindhoven (2007-2025), Elkerliek Hospital Helmond (2010-2025), Maxima Medical Center Veldhoven/Eindhoven (2007-2025), Jeroen Bosch Hospital Den Bosch (2013-2025), Laurentius Hospital Roermond (2007-2025), St. Annaziekenhuis Geldrop (2007-2025), St. Elisabeth Hospital Tilburg (2007-2009), St. Jans Gasthuis Weert (2007-2025), VieCuri Medical Center Venlo/Venray (2013-2025), all in the Netherlands. * Hospitals (and periods) were eligible for inclusion if (distant) registration from Maastricht UMC+ was possible. * The inclusion period may be prolonged after 2025. Exclusion Criteria: none
Where this trial is running
Maastricht
- Multiple hospitals in the Netherlands (see Eligibility) — Maastricht, Netherlands (RECRUITING)
Study contacts
- Study coordinator: Vivianne CG Tjan-Heijnen, MD, PhD
- Email: vcg.tjan.heijnen@mumc.nl
- Phone: +31 (0) 43 3877025
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, Breast neoplasms, Neoplasm Metastasis, Registry